Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | RDHL |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 5.6M |
| IPO Year | N/A | N/A |
| Metric | AYTU | RDHL |
|---|---|---|
| Price | $2.78 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | 141.4K | ★ 1.3M |
| Earning Date | 02-11-2026 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,696,000.00 | $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | $47.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.95 | $0.91 |
| 52 Week High | $3.07 | $6.80 |
| Indicator | AYTU | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 65.55 | 55.48 |
| Support Level | $2.65 | $0.91 |
| Resistance Level | $3.07 | $1.42 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 65.73 | 70.89 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.